Cargando…
mTOR Inhibition by Everolimus Does Not Impair Closure of Punch Biopsy Wounds in Renal Transplant Patients
BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors are approved to prevent allograft rejection and control malignancy. Unfortunately, they are associated with adverse effects, such as wound healing complications that detract from more extensive use. There is a lack of prospective wound heal...
Autores principales: | Dutt, Shelley B., Gonzales, Josephine, Boyett, Megan, Costanzo, Anne, Han, Peggy P., Steinberg, Steven, McKay, Dianne B., Jameson, Julie M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381740/ https://www.ncbi.nlm.nih.gov/pubmed/28405603 http://dx.doi.org/10.1097/TXD.0000000000000663 |
Ejemplares similares
-
Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023) -
One-year Outcome of Everolimus With Standard-dose Tacrolimus Immunosuppression in De Novo ABO-incompatible Living Donor Kidney Transplantation: A Retrospective, Single-center, Propensity Score Matching Comparison With Mycophenolate in 42 Transplants
por: Noguchi, Hiroshi, et al.
Publicado: (2019) -
Absence of Intragraft B Cells in Rejection Biopsies After Rituximab Induction Therapy: Consequences for Clinical Outcome
por: van den Hoogen, Martijn W.F., et al.
Publicado: (2017) -
Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients
por: van der Zwan, Marieke, et al.
Publicado: (2018) -
Outcomes of Living Kidney Donor Candidate Evaluations in the Living Donor Collective Pilot Registry
por: Kasiske, Bertram L., et al.
Publicado: (2021)